Count | |
| 2 | |
| 1 | |
| 1 | |
| 1 | |
| 3 | |
Dideoxynucleosides/adverse effects/pharmacokinetics/*therapeutic use | 1 |
| 2 | |
| 2 | |
Dideoxynucleosides/adverse effects/*pharmacokinetics/*therapeutic use | 1 |
| 3 | |
| 1 | |
| 8 | |
| 8 | |
| 2 | |
| 2 | |
| 1 | |
| 4 | |
| 1 | |
| 14 | |
| 1 | |
| 1 | |
| 1 | |
| 4 | |
| 1 | |
| 3 | |
| 2 | |
| 2 | |
| 3 | |
| 2 | |
| 1 | |
Dideoxynucleosides/administration & dosage/*therapeutic use/toxicity | 1 |
| 1 | |
Dideoxynucleosides/*chemical synthesis/chemistry/pharmacology | 1 |
Arginine/adverse effects/*analogs & derivatives/blood/*drug effects | 1 |
C-Reactive Protein/adverse effects/*drug effects/*metabolism | 1 |
Phosphoproteins/adverse effects/*antagonists & inhibitors/drug effects | 1 |
| 1 | |
| 1 | |
| 1 | |
| 1 | |
| 1 | |
| 4 | |
| 4 | |
| 2 | |
| 16 | |
| 6 | |
| 2 | |
| 1 | |
| 1 | |
| 1 | |
| 1 | |
| 1 | |
| 10 | |
| 1 | |
| 1 | |
| 1 | |
| 7 | |
| 1 | |
| 3 | |
| 5 | |
| 2 | |
| 1 | |
| 2 | |
| 3 | |
| 1 | |
| 1 | |
| 3 | |
| 2 | |
| 3 | |
| 2 | |
| 1 | |
| 3 | |
| 1 | |
| 1 | |
| 1 | |
| 1 | |
| 2 | |
| 2 | |
| 4 | |
| 1 | |
| 1 | |
| 2 | |
| 1 | |
| 1 | |
| 1 | |
| 1 | |
| 1 | |
| 1 | |
| 6 | |
| 3 | |
| 1 | |
| 1 | |
| 1 | |
| 3 | |
| 2 | |
| 1 | |
| 2 | |
| 1 | |
| 6 | |
| 2 | |